Details

Autor(en) / Beteiligte

• Kim, Yu‐Mi
• Choi, Jin‐Ouk
• Cho, Yong‐Joon
• Hong, Bong‐Ki
• Shon, Hoh‐Jeong
• Kim, Bum‐Joon
• Park, Joo‐Hong
• Kim, Wan‐Uk
• Kim, Donghyun

Titel

Mycobacterium potentiates protection from colorectal cancer by gut microbial alterations

Ist Teil von

• Immunology, 2023-03, Vol.168 (3), p.493-510

Ort / Verlag

England: Wiley Subscription Services, Inc

Erscheinungsjahr

2023

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• Not only are many Mycobacteria pathogens, but they can act as strong non‐specific immunopotentiators, generating beneficial effects on the pathogenesis of some diseases. However, there has been no direct evidence of the effect of mycobacterial species on colorectal cancer (CRC). Herein, we showed that there may be a meaningful inverse correlation between the incidence of tuberculosis and CRC based on global statistics and that heat‐killed Mycobacterial tuberculosis and live Mycobacterium bovis (Bacillus Calmette–Guérin strain) could ameliorate CRC development. In particular, using a faecal microbiota transplantation and a comparison between separate housing and cohousing, we demonstrated that the gut microbiota is involved in the protective effects. The microbial alterations can be elucidated by the modulation of antimicrobial activities including those of the Reg3 family genes. Furthermore, interleukin‐22 production by T helper cells contributed to the anti‐inflammatory activity of Mycobacteria. Our results revealed a novel role of Mycobacteria involving gut microbial alterations in dampening inflammation‐associated CRC and an immunological mechanism underlying the interaction between microbes and host immunity. Subcutaneous injection of heat‐killed Mycobacterial tuberculosis or live Mycobacterium bovis Bacillus Calmette–Guérin strain ameliorates the development of colorectal cancer (CRC), in which the gut microbiota is involved. The mycobacteria can induce IL‐22 production from CD4+ T cells, which leads to the secretion of antimicrobial peptides, such as Reg3β and Reg3γ, from epithelial cells to the lumen. The increased antimicrobial peptides can elucidate the mycobacteria‐mediated gut microbial alteration. Collectively, mycobacteria have the potential to change the gut microbial structure to more beneficial members, thereby protecting from CRC.